Comparison of the renal outcomes of novel antidiabetic agents in type 2 diabetes with chronic kidney disease: a network meta-analysis

A network meta-analysis of 20 randomized trials in over 80,000 patients found that SGLT2 inhibitors—led by dapagliflozin—provide the most consistent kidney protection in type 2 diabetes with chronic kidney disease, while DPP-4 inhibitors conferred no renal benefit.